US FDA extends action date for BMS/AZ's diabetes drug as it assesses new data
27 October 2011
Pial Ganguli
Please Login to read the full article.
27 October 2011
Pial Ganguli
Please Login to read the full article.
RELATED CONTENT
NEWS
- US FDA rejects AZ/BMS diabetes drug dapagliflozin
- US FDA panel rejects BMS/AstraZeneca diabetes drug on cancer, liver injury concerns
- Cancer a concern for BMS/AstraZeneca drug, but liver injury could be FDA panel focus
- FDA rejection of Dapagliflozin creates uncertainty for other SGLT-2 inhibitors
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
